

Contents

Chapter 1

Immune Privilege of Corneal Allografts

Jerry Y. Niederkorn

1.1	History of Corneal Transplantation and Immune Privilege	1
1.2	How Successful Is Corneal Transplantation?	2
1.3	Immune Rejection of Corneal Allografts	3
1.3.1	Role of CD4+ T Lymphocytes in Corneal Allograft Rejection	3
1.3.2	Role of CD8+ T Lymphocytes in Corneal Allograft Rejection	3
1.3.3	Role of Antibodies in Corneal Allograft Rejection	4
1.3.4	Role of Macrophages and NK Cells in Corneal Allograft Rejection	4
1.3.5	What are the Effectors of Corneal Allograft Rejection?	5
1.4	Role of Atopic Diseases in Corneal Allograft Rejection	5
1.5	Immune Privilege of Corneal Allografts Is a Tripartite Phenomenon	5
1.5.1	Afferent Blockade of the Immune Response to Corneal Allografts	6
1.5.2	Immune Deviation in the Central Processing Component of the Immune Reflex Arc	8
1.5.3	Efferent Blockade of the Immune Response to Corneal Allografts	9
	References	10

Chapter 2

Mechanisms of Corneal Allograft Rejection and the Development of New Therapies

Douglas J. Coster, Claire F. Jessup, and Keryn A. Williams

2.1	Status of Corneal Transplantation	13
2.2	Success Rate of Corneal Transplantation	13
2.3	Maintenance and Erosion of Corneal Privilege	14

2.4	The Corneal Allograft Response	15
2.5	Antigen Uptake in the Eye	15
2.6	Antigen Processing	16
2.7	Antigen Presentation	16
2.8	T Cell Activation, Proliferation, and Clonal Expansion	17
2.9	Effector Arm of the Allograft Response	17
2.10	Current Management of Corneal Transplants	17
2.11	Prevention of Allograft Rejection	17
2.12	Stratification of Risk	18
2.13	Protecting Immune Privilege	18
2.14	Minimizing Antigenic Differences Between Donor and Recipient	18
2.15	Systemic Immunosuppression	18
2.16	Surgical Techniques and Postoperative Management	18
2.17	Management of Acute Rejection Episodes	19
2.18	New Therapies with Novel Mechanisms	19
2.19	Antibody-based Immunosuppressive Agents in Transplantation	19
2.20	Engineered Antibodies for Eye Disease	19
2.21	Gene Therapy of the Donor Cornea	20
2.22	Vectors for Gene Therapy of the Cornea	20
2.23	Transgenes for Prolonging Corneal Graft Survival	20
2.24	Future Prospects	20
	References	22

Chapter 3

New Developments in Topical and Systemic Immunomodulation Following Penetrating Keratoplasty

Alexander Reis and Thomas Reinhard

3.1	Introduction	25
3.2	Immunology	26
3.2.1	Acute Rejection	26
3.2.2	Major Histocompatibility Complex (MHC)	26

3.2.2.1	Direct Pathway of Allorecognition	26	4.1.1	Anterior Chamber-Associated Immune Deviation (ACAID)	38
3.2.2.2	Indirect Pathway of Allorecognition.....	26	4.1.2	The Th1/Th2 Paradigm	38
3.2.3	Chronic Rejection	26	4.2	Pitfalls in the Determination of Cytokine Levels from Aqueous Humor.....	38
3.3	Normal-risk vs. High-risk Transplantation	27	4.3	Relevance of Individual Cytokines in Corneal Transplantation.....	40
3.3.1	Normal-risk Transplantation	27	4.3.1	Interleukin 1b.....	40
3.3.2	High-risk Transplantation.....	27	4.3.1.1	General Functions from In Vitro Experiments	40
3.3.3	Rationale for Systemic Immunosuppression	27	4.3.1.2	Effects in Animal Models of Corneal Transplantation	40
3.3.4	Why Is Immunomodulation with Topical Steroids Not Sufficient to Prevent Immunologic Graft Rejection in High-Risk Patients?	27	4.3.1.3	Interleukin 1b Levels in Human Aqueous Humor	40
3.3.5	Rationale for Topical Immunomodulation.....	27	4.3.2	Interleukin 2	40
3.4	Immunosuppressive Agents.....	28	4.3.2.1	General Functions from In Vitro Experiments	40
3.4.1	History.....	28	4.3.2.2	Effects in Animal Models of Corneal Transplantation	40
3.4.2	Corticosteroids.....	28	4.3.2.3	Interleukin 2 Levels in Human Aqueous Humor.....	40
3.4.3	Cyclosporine A	28	4.3.3	Interleukin 6	41
3.4.3.1	CSA in Corneal Transplantation	29	4.3.3.1	General Functions from In Vitro Experiments	41
3.4.4	Tacrolimus (fk506).....	29	4.3.3.2	Effects in Animal Models of Corneal Transplantation	41
3.4.4.1	Tacrolimus in Corneal Transplantation ..	29	4.3.3.3	Interleukin 6 Levels in Human Aqueous Humor.....	41
3.4.5	Mycophenolate Mofetil (MMF).....	29	4.3.4	Interleukin 10.....	41
3.4.6	Rapamycin (Sirolimus).....	30	4.3.4.1	General Functions from In Vitro Experiments	41
3.4.7	RAD (Everolimus).....	30	4.3.4.2	Effects in Animal Models of Corneal Transplantation	41
3.4.8	FTY 720.....	31	4.3.4.3	Interleukin10 Levels in Human Aqueous Humor	41
3.4.9	FK788.....	31	4.3.5	Interferon Gamma (IFN- γ).....	42
3.5	Pimecrolimus	31	4.3.5.1	General Functions from In Vitro Experiments	42
3.5.1	Pimecrolimus in Corneal Transplantation	31	4.3.5.2	Effects in Animal Models of Corneal Transplantation	42
3.5.2	Biologic Agents	31	4.3.5.3	INF- γ Levels in the Aqueous Humor	42
3.5.2.1	Basiliximab and Daclizumab.....	31	4.3.6	Tumor Necrosis Factor Alpha (TNF- α) ...	42
3.6	Guidelines for Practitioners	32	4.3.6.1	General Functions from In Vitro Experiments	42
3.6.1	Systemic Immunosuppression with Drugs with Proven Efficacy in Corneal Transplantation.....	32	4.3.6.2	Effects in Animal Models of Corneal Transplantation	42
3.6.1.1	Preoperative Evaluation	32	4.3.6.3	TNF- α Levels in Human Aqueous Humor.....	42
3.6.1.2	How to Use Cyclosporine in High-risk Corneal Transplantation	32	4.3.7	Transforming Growth Factor Beta (TGF- β)	43
3.6.1.3	How to Use MMF in High-risk Corneal Transplantation	32	4.3.7.1	General Functions from In Vitro	
3.6.2	Topical Immunosuppression.....	33			
3.7	Conclusion.....	33			
	References.....	33			
Chapter 4					
Cytokines Analysis of the Aqueous Humor in the Context of Penetrating Keratoplasty					
Philip Maier and Thomas Reinhard					
4.1	Immune Privilege of the Anterior Ocular Segment.....	38			

Experiment	43	5.3.3	Surgical Options for Total Limbal Stem Cell Deficiency	57
4.3.7.2 Effects in Animal Models of Corneal Transplantation	44	5.4	Surgical Techniques for Transplanting Corneal Limbal Stem Cells	58
4.3.7.3 TGF- β 2 Levels in Human Aqueous Humor	44	5.4.1	Conjunctival Limbal Autograft (CLAU)...	58
4.3.8 Fas, Fas Ligand and Soluble Fas Ligand	44	5.4.2	Living-Related Conjunctival Limbal Allograft Transplant (Ir-CLAL)....	58
4.3.8.1 General Functions from In Vitro Experiments	44	5.4.2.1	Clinical Outcomes of CLAU and Ir-CLAL...	59
4.3.8.2 Effects in Animal Models of Corneal Transplantation	45	5.4.3	Keratolimbal Allograft Transplant	59
4.3.8.3 sFasL Levels in Human Aqueous Humor	45	5.4.4	Ex Vivo Expansion and Transplantation of Cultured Limbal Stem Cells	60
4.3.9 Further Cytokines and Immunomodulative Factors	45	5.4.5	Regulations Governing the Clinical Use of Ex vivo Cultured Tissue	60
4.3.9.1 Interleukin 1 Receptor Antagonist	45	5.4.6	Evidence of the Presence of Stem Cells in Ex vivo Cultures and Grafts.....	61
4.3.9.2 Interleukin 4	46	5.4.7	Assessing Outcomes Following LESC Transplantation	61
4.3.9.3 Interleukin 5	46	5.4.8	Evidence for Donor Cell Survival Following Ex Vivo Cultured LESC Transplantation	61
4.3.9.4 Interleukin 8	46	5.4.9	Role of Tissue Matching in Transplantation of Allogeneic Tissue or Cells	62
4.3.9.6 Alpha-Melanocyte-Stimulating Hormone/Calcitonin Gene-Related Peptide/Thrombospondin/ Somatostatin	46	5.4.10	Alternative Sources of Autologous Stem Cells	62
4.4 Cytokine Profiles in the Context of Corneal Transplantation	49	5.4.11	Issues Surrounding Ex Vivo Cultured LESC Transplantation that Require Further Investigation	62
4.4.1 Cytokine Profiles in Animal Models	49	5.5	Conclusion.....	63
4.4.2 Cytokine Profiles in Humans	49		References	63
4.4.2.1 Cytokines in the Serum of Patients Following PK	49			
4.4.2.2 Cytokines in Human Corneas	49			
4.4.2.3 Cytokines in Human Aqueous Humor ...	49			
References	50			

Chapter 5

Limbal Stem Cell Transplantation: Surgical Techniques and Results

Alex J. Shortt, Stephen J. Tuft, and Julie T. Daniels

5.1	Introduction	53	6.1	Relationship of Endothelial Barrier Function to Corneal Transparency	70
5.1.1	The Corneal Epithelium	53	6.2	Corneal Endothelial Cell Loss and Repair Mechanisms	71
5.1.2	The Limbus and Corneal Epithelial Homeostasis	53	6.2.1	Causes of Cell Loss	71
5.2	Corneal LESC Deficiency.....	55	6.2.2	Repair of the Endothelial Monolayer	71
5.2.1	Diagnosis and Classification of Corneal LESC Deficiency	55	6.3	Are Human Corneal Endothelial Cells Able to Divide?.....	71
5.3	Management of Patients with Limbal Stem Cell Deficiency	57	6.3.1	Proliferative Status In Vivo	71
5.3.1	Conservative Options	57	6.3.2	Evidence that HCEC Retain Proliferative Capacity.....	71
5.3.2	Surgical Options for Partial Limbal Stem Cell Deficiency	57	6.4	The Cell Cycle	72
			6.4.1	Positive Regulation of the Cell Cycle	72
			6.4.2	Negative Regulation of G1-Phase of the Cell Cycle	73

Chapter 6

Cell Cycle Control and Replication in Corneal Endothelium

Nancy C. Joyce

6.5	Potential Causes for Inhibition of HCEC Proliferation In Vivo	74	7.3.2.4	Hybrid Lenses	89
6.5.1	Cell–Cell Contacts Inhibit Division	74	7.3.3	Fitting Techniques	89
6.5.2	Endothelium In Vivo Lacks Effective Paracrine or Autocrine Growth Factor Stimulation	75	7.3.3.1	The Reshape and Splint Method	89
6.5.3	TGF-Beta2 Has a Suppressive Effect on S-phase Entry	75	7.3.3.2	The Three-Point Touch Method	89
6.6	Proliferative Capacity of HCEC Differs with Donor Age	76	7.3.3.3	The Apical Clearance Method	90
6.6.1	Analysis of pRb Hyperphosphorylation ..	77	7.3.3.4	Scleral Fitting Method	90
6.6.2	Analysis of Replication Competence	77	7.3.4	GP Fitting Following Cross Linking	90
6.6.3	Analysis of CKI Protein Expression	77	7.4	CL Fitting Following Penetrating Keratoplasty	91
6.7	Efforts to Stimulate Corneal Endothelial Proliferation by Interfering with G1-phase Inhibition	78	7.4.1	Indications for CLs Following PK	91
6.7.1	Overcoming G1-phase Inhibition	79	7.4.2	Indications for CLs Following PK in Comparison with Newer Techniques	91
6.7.2	Bypassing G1-phase Inhibition	79	7.4.3	PK Peculiarities in Conjunction with CLs ...	92
6.8	Endothelial Topography Affects the Proliferative Capacity of HCEC	79	7.4.3.1	Corneal Sensitivity, Fitting Quality, and Frequent Follow-Ups	92
6.8.1	Differences in Proliferative Capacity	79	7.4.3.2	The Endothelium and Choice of GP Materials	92
6.8.2	Differences in Senescence Characteristics	80	7.4.3.3	Immune Reactions	92
6.9	Identification of Mechanisms Responsible for Decreased Proliferative Capacity	80	7.4.4	When to Fit?	92
6.9.1	Are Critically Short Telomeres Responsible for Decreased Proliferative Capacity?	81	7.4.5	Fitting Techniques	93
6.9.2	Is Sub-lethal Oxidative DNA Damage Responsible for Decreased Proliferative Capacity?	81	7.4.5.1	PK with One or Two Sutures	93
6.10	Future Directions	82	7.4.5.2	CL Fitting Following Suture Removal	93
	References	83		Abbreviations	94
				References	94
Chapter 7			Chapter 8		
Current State of the Art of Fitting Gas-Permeable (GP) Contact Lenses			Allergic Disease of the Conjunctiva and Cornea		
Silke Lohrengel and Dieter Muckenhirn			Andrea Leonardi		
7.1	Corneal Topography and Automatic Fitting Programs	87	8.1	Introduction and Classification	97
7.2	Fitting CLs	88	8.2	Clinical Forms	98
7.3	The Keratoconus	88	8.2.1	Seasonal and Perennial Allergic Conjunctivitis	98
7.3.1	KC Peculiarities in Conjunction with CL	88	8.2.2	Vernal Keratoconjunctivitis	98
7.3.1.1	Corneal Sensitivity and Maximum Resilience	88	8.2.3	Atopic Keratoconjunctivitis	100
7.3.1.2	Corneal Contour: KC Stage: KC Type	89	8.2.4	Giant Papillary Conjunctivitis	101
7.3.2	Forms of Correction	89	8.2.5	Contact Blepharoconjunctivitis	101
7.3.2.1	Soft Lenses	89	8.2.6	Drug-Induced Conjunctivitis or Keratoconjunctivitis	101
7.3.2.2	GP Contact Lenses	89	8.2.7	Urban Eye Allergy Syndrome	102
7.3.2.3	Piggyback	89	8.3	Differential Diagnosis	103
			8.4	Diagnostic Tests in Ocular Allergy	104
			8.5	Ocular Immunity and the Allergic Reaction	104
			8.5.1	Innate Immunity and Ocular Allergy	104
			8.5.2	The Allergic Process	105
			8.5.3	Allergic Inflammation	106
			8.6	The Cornea in Allergic Diseases	107
			8.6.1	Corneal Immunology	107
			8.6.2	Allergic Inflammation and Corneal Damage	107
			8.6.3	Tear Instability and Corneal Involvement ..	107
			8.6.4	Corneal Clinical Manifestations	

8.6.5	in Ocular Allergy	108
8.6.5	Confocal Microscopy and Allergic Keratoconjunctivitis	108
8.6.6	Keratoconus and Allergic Conjunctivitis	109
8.6.7	Keratoglobus	109
8.6.8	Allergic Keratoconjunctivitis and Corneal Infection	110
8.6.9	Allergy and Corneal Transplant	110
8.6.9.1	Immunology	110
8.6.9.2	Clinical Outcomes	111
8.7	Treatment of Ocular Allergy	111
8.7.1	Nonpharmacological Management	112
8.7.2	Treatment of Allergic Conjunctivitis	112
8.7.2.1	Topical Ocular Pharmacological Treatment	112
8.7.2.2	Topical Nonocular Pharmacological Treatment	113
8.7.2.3	Systemic Pharmacological Treatment	113
8.7.2.4	Specific Immunotherapy	114
8.7.3	Treatment of GPC	114
8.7.4	Treatment of Vernal Keratoconjunctivitis	114
8.7.4.1	Corticosteroids	114
8.7.4.2	Cyclosporine and Other Immunosuppressive Treatments	115
8.7.5	Treatment of AKC	115
8.7.5.1	Cyclosporine and Other Immunosuppressive Treatments	115
8.7.6	Surgical Treatment of Keratoconjunctivitis	116
	References	116

Chapter 9 Trachoma

Matthew J. Burton

9.1	Introduction	121
9.1.1	Overview	121
9.1.2	History	121
9.2	Clinical Features	122
9.2.1	Symptoms and Signs	122
9.2.2	Trachoma Grading Systems	123
9.2.3	Differential Diagnosis	123
9.3	Chlamydia Trachomatis	123
9.4	Laboratory Diagnosis	124
9.5	Clinical Signs and Infection	125
9.6	Epidemiology	125
9.6.1	Prevalence and Distribution	125
9.6.2	Age and Gender	126
9.6.3	Risk Factors for Active Trachoma and <i>C. Trachomatis</i> Infection	126
9.7	Pathophysiology of Trachoma	127

9.7.1	The Stimulus for Inflammation and Scarring in Trachoma	127
9.7.2	Histopathology	128
9.7.3	The Immune Response in Trachoma	128
9.7.4	Immunopathogenesis of Conjunctival Scarring	129
9.8	Trachoma Control	130
9.8.1	The SAFE Strategy	130
9.8.2	Surgery for Trichiasis	130
9.8.3	Antibiotics	130
9.8.4	Face Washing	132
9.8.5	Environmental Improvements	132
9.10	Conclusion	132
	References	133

Chapter 10 Keratoprosthesis

Jason J. Jun, Donna E. Siracuse-Lee, Mary K. Daly, and Claes H. Dohlman

10.1	Introduction	137
10.2	Prognostic Hierarchy	138
10.3	Defining Patient Subtypes	138
10.3.1	Patient Subtype A: The Noninflamed Eye	138
10.3.2	Patient Subtype B: The Inflamed Eye	138
10.4	Experience with Kpro in Patient Subtype A	138
10.4.1	Boston Type 1 Kpro	138
10.4.1.1	Pediatric Application of Boston Type 1 Kpro	139
10.4.2	AlphaCor Kpro	140
10.5	Experience with Kpro in Patient Subtype B	140
10.5.1	Osteo-Odonto Keratoprosthesis (OOKP) ...	140
10.5.2	Boston Type 2 Kpro	141
10.6	Other Kpro Designs	141
10.6.1	Pintucci Kpro	141
10.6.2	Seoul-Type Kpro	141
10.6.3	Worst-Singh Kpro	141
10.6.4	Russian/Ukrainian Experience	142
10.7	New Directions in Kpro Research	142
10.7.1	Hydroxyapatite Biologic Haptics	142
10.7.2	Biologic Coatings	142
10.7.3	Biologic Scaffolds and Enhanced Hydrogels	142
10.8	Conclusion	142
	References	143

Chapter 11 Posterior Lamellar Keratoplasty in Perspective

Arnalich-Montiel F and Dart JKG

11.1	Introduction	145
------	--------------------	-----

11.2	Choosing Endothelial Keratoplasty Procedures.....	146	11.3.7.3	Anterior Chamber Lens.....	153
11.2.1	Indications.....	146	11.4	Clinical Results and Complications.....	153
11.2.2	Preoperative Considerations.....	146	11.4.1	Visual Acuity.....	153
11.2.2.1	Confirming the Extent of Endothelial Dysfunction.....	146	11.4.2	Astigmatism.....	153
11.2.2.2	Corneal Scarring.....	147	11.4.3	Spherical Equivalent.....	153
11.2.2.3	Cataract and Intraocular Lens Status.....	147	11.4.4	Endothelial Cell Loss.....	154
11.2.2.4	Lens/Iris Diaphragm Status.....	147	11.4.5	Corneal Donor Dislocation (Fig. 11.4a–c).....	155
11.2.2.5	Intraocular Pressure.....	148	11.4.6	Pupillary Block.....	156
11.2.2.6	Retinal Function.....	148	11.4.7	Primary Graft Failure.....	156
11.3	PLK Surgical Technique.....	148	11.4.8	Rejection.....	156
11.3.1	Donor Preparation.....	148	11.4.9	Other Complications.....	156
11.3.2	Host Dissection for DSEK/DSAEK.....	148	11.5	Conclusion.....	157
11.3.3	Donor Insertion.....	149		References.....	157
11.3.4	Techniques for Graft Centration.....	149	Index		161
11.3.5	Techniques for Promoting Donor Adhesion.....	150			
11.3.6	Post-operative Care.....	151			
11.3.7	Surgery for Complex Cases.....	151			
11.3.7.1	Failed Grafts.....	151			
11.3.7.2	Aniridics, Vitrectomised and Aphakic Eyes (Fig. 11.3e).....	153			